KR20150047510A - 미토콘드리아 관련 질환의 치료에서 사용하기 위한 알파-1-마이크로글로불린 - Google Patents

미토콘드리아 관련 질환의 치료에서 사용하기 위한 알파-1-마이크로글로불린 Download PDF

Info

Publication number
KR20150047510A
KR20150047510A KR1020157005748A KR20157005748A KR20150047510A KR 20150047510 A KR20150047510 A KR 20150047510A KR 1020157005748 A KR1020157005748 A KR 1020157005748A KR 20157005748 A KR20157005748 A KR 20157005748A KR 20150047510 A KR20150047510 A KR 20150047510A
Authority
KR
South Korea
Prior art keywords
deficiency
mitochondrial
microglobulin
alpha
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157005748A
Other languages
English (en)
Korean (ko)
Inventor
보 아케르스트룀
마그너스 그람
레나 로젠뢰프
Original Assignee
에이원엠 파마 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이원엠 파마 에이비 filed Critical 에이원엠 파마 에이비
Publication of KR20150047510A publication Critical patent/KR20150047510A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020157005748A 2012-09-05 2013-09-04 미토콘드리아 관련 질환의 치료에서 사용하기 위한 알파-1-마이크로글로불린 Ceased KR20150047510A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201270538 2012-09-05
DKPA201270538 2012-09-05
DKPA201270557 2012-09-12
DKPA201270557 2012-09-12
PCT/EP2013/068270 WO2014037390A1 (en) 2012-09-05 2013-09-04 Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases

Publications (1)

Publication Number Publication Date
KR20150047510A true KR20150047510A (ko) 2015-05-04

Family

ID=49162118

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157005748A Ceased KR20150047510A (ko) 2012-09-05 2013-09-04 미토콘드리아 관련 질환의 치료에서 사용하기 위한 알파-1-마이크로글로불린

Country Status (21)

Country Link
US (1) US10226507B2 (https=)
EP (1) EP2900254B1 (https=)
JP (2) JP2015533790A (https=)
KR (1) KR20150047510A (https=)
CN (1) CN104661673A (https=)
AU (1) AU2013311714C1 (https=)
BR (1) BR112015003957A2 (https=)
CA (1) CA2881321A1 (https=)
DK (1) DK2900254T3 (https=)
EA (1) EA028963B1 (https=)
ES (1) ES2599034T3 (https=)
HR (1) HRP20161364T1 (https=)
HU (1) HUE030559T2 (https=)
IN (1) IN2015DN00515A (https=)
MX (1) MX357656B (https=)
NZ (1) NZ629621A (https=)
PL (1) PL2900254T3 (https=)
PT (1) PT2900254T (https=)
SG (1) SG11201500669SA (https=)
WO (1) WO2014037390A1 (https=)
ZA (1) ZA201500547B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016204360A (ja) * 2015-02-25 2016-12-08 エー１エム ファーマ エービーＡ１Ｍ Ｐｈａｒｍａ ＡＢ 放射性核種療法における腎臓の保護に用いるためのアルファ−１−ミクログロブリン
WO2017144674A1 (en) * 2016-02-25 2017-08-31 A1M Pharma Ab Alpha-1-microglobulin for use in the protection of kidneys in connection with use of contrast media
JP6976579B2 (ja) 2016-03-18 2021-12-08 ガード セラピューティクス インターナショナル エービーGuard Therapeutics International AB 新規アルファ−１−マイクログロブリン由来タンパク質ならびにそれらの使用
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
CN109867717A (zh) * 2019-04-01 2019-06-11 山西瑞亚力生物技术有限公司 一种血浆中α1微球蛋白的提取方法
CN110452980B (zh) * 2019-09-23 2023-07-28 武汉儿童医院 一种线粒体脑肌病诊断试剂盒及应用
US20220362293A1 (en) * 2019-09-25 2022-11-17 Cytegen Corp. Treatment of Mitochondrial Deficits and Age-Related Diseases Using Blood Products
CN115575646B (zh) * 2022-11-21 2023-04-28 四川大学华西医院 一种代谢标志物组在制备预测癫痫发作的试剂盒中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2547124A1 (en) * 2003-11-26 2005-06-09 Sanofi-Aventis Deutschland Gmbh Tubular proteinuria as an indicator for elevated cardiovascular risk
WO2008098734A1 (en) * 2007-02-12 2008-08-21 Stefan Hansson Diagnosis and treatment of preeclampsia
WO2009098682A2 (en) * 2008-02-04 2009-08-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for treatment of mitochondrial disorders
HRP20160760T1 (hr) * 2008-07-18 2016-08-12 A1M Pharma Ab Medicinska uporaba čistača radikala i antioksidacijskog alfa-1-mikroglobulina

Also Published As

Publication number Publication date
IN2015DN00515A (https=) 2015-06-26
WO2014037390A1 (en) 2014-03-13
US10226507B2 (en) 2019-03-12
SG11201500669SA (en) 2015-02-27
EA201590503A1 (ru) 2015-06-30
MX2015002604A (es) 2015-06-10
AU2013311714A1 (en) 2015-03-12
HRP20161364T1 (hr) 2016-12-16
EP2900254A1 (en) 2015-08-05
US20150258171A1 (en) 2015-09-17
CA2881321A1 (en) 2014-03-13
AU2013311714B2 (en) 2017-10-12
HUE030559T2 (en) 2017-05-29
HK1210585A1 (en) 2016-04-29
EA028963B1 (ru) 2018-01-31
BR112015003957A2 (pt) 2017-08-08
MX357656B (es) 2018-07-18
PL2900254T3 (pl) 2017-02-28
ZA201500547B (en) 2017-09-27
AU2013311714C1 (en) 2018-01-25
JP2018203756A (ja) 2018-12-27
ES2599034T3 (es) 2017-01-31
CN104661673A (zh) 2015-05-27
NZ629621A (en) 2015-09-25
JP2015533790A (ja) 2015-11-26
EP2900254B1 (en) 2016-08-03
PT2900254T (pt) 2016-10-18
DK2900254T3 (en) 2016-08-29

Similar Documents

Publication Publication Date Title
KR20150047510A (ko) 미토콘드리아 관련 질환의 치료에서 사용하기 위한 알파-1-마이크로글로불린
Liu et al. Rhein attenuates cerebral ischemia-reperfusion injury via inhibition of ferroptosis through NRF2/SLC7A11/GPX4 pathway
Ebeling et al. Improving retinal mitochondrial function as a treatment for age-related macular degeneration
Galloway et al. Mitochondrial morphology—emerging role in bioenergetics
Yin et al. NDRG2 protects the brain from excitotoxicity by facilitating interstitial glutamate uptake
Wei et al. Neuroglobin is an endogenous neuroprotectant for retinal ganglion cells against glaucomatous damage
CN104023736A (zh) Jnk信号转导途径的细胞-可渗透肽抑制剂用于治疗干眼综合征的用途
Gupta et al. TrkB receptor agonist 7, 8 dihydroxyflavone is protective against the inner retinal deficits induced by experimental glaucoma
Magharious et al. Quantitative iTRAQ analysis of retinal ganglion cell degeneration after optic nerve crush
Lo et al. Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2
Geng et al. Mammalian STE20-like kinase 1 knockdown attenuates TNFα-mediated neurodegenerative disease by repressing the JNK pathway and mitochondrial stress
JP2020536065A (ja) 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
Argenti The role of mitochondrial dysfunction in Huntington's disease: pathogenesis and its relation with striatal Rhes protein
KR102040893B1 (ko) Arl6ip1의 유전성 강직성 하반신마비의 치료 용도
HK1210585B (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
Dal Cortivo et al. Protein delivery to the eye: assessing therapeutic potential across inner and outer retina
Li et al. Protective effect of apelin-13 in lens epithelial cells via inhibiting oxidative stress-induced apoptosis
Vijayasarathy et al. Organization and molecular interactions of retinoschisin in photoreceptors
Jones The role of optic atrophy 1 (OPA1) in the evolution of brain damage after neonatal hypoxic-ischaemic insult
KR20240155868A (ko) 외상성 뇌손상의 치료 방법
CN106999579A (zh) 可辨识致病性tdp‑43的抗体及其用途
Matthiessen et al. Loss of ciliary proteins IFT20 and IFT88 results in defective phagocytosis and metabolism in the RPE
Alassaf Pregnancy associated plasma protein-aa is a novel regulator of neuron survival
Deheshi Mitochondrial form and function: an investigation of the mechanism and significance of mitochondrial remodelling in rat cortical astrocytes
Uggenti Modification of mutant bestrophin-1 processing to prevent retinal degeneration

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000